Loading clinical trials...
Loading clinical trials...
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Conditions
Interventions
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Locations
16
United States
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
Bentonville, Arkansas, United States
83 AR Pediatric Clinical Research 500 South University, Ste. 200
Little Rock, Arkansas, United States
32 Prem Health Research Center 9317 Firestone Blvd.
Downey, California, United States
27 KY Pediatric Adult Research 201 South 5th Street, Suite 102
Bardstown, Kentucky, United States
36 Meridian Clinical Research 3319 N. 107th Street
Omaha, Nebraska, United States
33 Dr. Sender's and Associates 2054 South Green Road
Cleveland, Ohio, United States
Start Date
May 1, 2013
Primary Completion Date
October 1, 2013
Completion Date
June 1, 2014
Last Updated
August 15, 2014
NCT01725217
NCT03694405
NCT04358731
NCT01896596
NCT02811120
NCT03089086
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions